GlassScriptPhysician profile
Michael Mendoza
NPI 1366769705
$1,202.77
in general payments reported to CMS, 2019-2025
13 companies · $566 in 2025
The $566 reported for 2025 was more than what 76% of Pediatric Gastroenterology providers received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.96 · 2021: $18.11 · 2023: $122 · 2024: $473 · 2025: $566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,160.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $325.72 | 2024-2025 | Sucraid, Sucraid |
| Mirum Pharmaceuticals, INC. | $248.22 | 2023-2025 | Livmarli |
| Takeda Pharmaceuticals U.S.A., INC. | $149.76 | 2024-2025 | Gattex, Eohilia |
| Regeneron Healthcare Solutions, INC. | $110.79 | 2023-2025 | Dupixent |
| Janssen Biotech, INC. | $83.03 | 2024-2025 | Stelara, Tremfya, Simponi Aria |
| Ucb, INC. | $82.06 | 2021-2024 | Briviact |
| Ipsen Biopharmaceuticals, INC | $67.11 | 2024-2025 | Bylvay |
| Abbvie INC. | $48.63 | 2023-2025 | |
| Ironwood Pharmaceuticals, INC | $24.53 | 2024 | |
| Portola Pharmaceuticals, LLC | $23.13 | 2019 | |
| Phadia US INC. | $20.38 | 2024 | Immunocap |
| Coloplast Corp | $18.58 | 2023 | Peristeen |
| Travere Therapeutics, INC. | $0.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mendoza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.